More than half of participants we interviewed agreed that the UK would take at least three years for its healthcare industry to stabilize in the event of a “No Deal” Brexit. Currently the pharmaceutical industry is a leading sector of wealth, with a growth value added to the UK economy of £13.8M ($21.7M*) in 2016. GlaxoSmithKline and AstraZeneca are UK-headquartered and generated combined global sales of over $61B in 2018 alone. The UK also has sizeable operations from leading multinational companies such as Pfizer, Roche, Novartis, and Johnson & Johnson (J&J).
Find out more about the key factors expected to impact the UK healthcare industry after Brexit